Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults [Globe and Mail, The (Toronto, Canada)]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Globe and Mail, The
Yorvipath ® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath ® , was developed by Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis"). Read more at newswire.ca This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026GlobeNewswire
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.MarketBeat
- RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/14/26 - Form 6-K
- 1/13/26 - Form 144
- ASND's page on the SEC website